Floatz logo

Dolutegravir

HTLV-1 Infection

Carlos BritesSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the HTLV-1 Infection cohort.

Asset / SponsorPhaseRating
Nivolumab
Mayo Clinic
Phase 2B
tenofovir
Carlos Brites
Phase 2CCC
DACLIZUMAB
National Cancer Institute (NCI)
Phase 1/2CCC
cc-5013
National Cancer Institute (NCI)
Phase 1CC
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 1CC

View all 9 →

Same molecule, other indications

Dolutegravir is also rated in:

HIV infectious diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
lipodystrophyDormant
BBB
Indicative ·
73 / 100
View asset →
HIV InfectionsDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →